Disease relevance of N-Butyl-N-nitrosourea

• Two clonal leukemia cell lines exhibiting diploidy or tetraploidy were isolated separately from a mother cell population of rat myelogenous leukemia DBLA-6 (induced by 1-butyl-1-nitrosourea), and their biologic characteristics altered during serial iv or ip passages in Donryu rats were examined [1].
• Cytogenetic studies were done on 34 primary leukemias induced by N-nitroso-N-butylurea (NBU) in outbred Long-Evans rats [2].
• The persistence of O6-n-butyldeoxyguanosine (O6-nBudG) in DNA, the presence of O6-alkylguanine DNA alkyltransferase (AT) activity in cell extracts, and cell survival following exposure to N-n-butyl-N-nitrosourea (BNU), have been measured in normal and xeroderma pigmentosum cell strains, both transformed and untransformed [3].
• On the other hand, the MTAA was not detected in the other types of tumors induced by ENU or BNU , i.e. gastric cancer, intestinal tumor, brain tumor, kidney tumor, bladder tumor, hemangioma, rhabdomyosarcoma, or leukemia [4].
• Butylnitrosourea (BNU) was used to induce thymic lymphomas in BDF1 mice [5].

Psychiatry related information on N-Butyl-N-nitrosourea

• BDF1 mice were exposed to butylnitrosourea for 12 weeks (BNU, 0.02% in the drinking water) and died of thymic lymphomas with median latency periods of 12-20 weeks [6].

High impact information on N-Butyl-N-nitrosourea

• Induction of hepatic tumors by diethylstilbestrol alone or in synergism with n-nitrosobutylurea in castrated male WF rats [7].
• 2 trisomy, and markers involving chromosome No. 2 were established from three 7,12-dimethylbenz[a]anthracene (DMBA)- and two N-butyl-N-nitrosourea (BNU)-induced erythroblastic leukemias in noninbred Long-Evans rats [8].
• Involvement of chromosome No. 2 in chromosome changes in primary leukemia induced in rats by N-nitroso-N-butylurea [2].
• The method was applied to evaluate O6BuG levels in DNA butylated in vitro with 10 mM N-nitroso-Nr-butylurea or isolated from rats given an i.p. dose of 185 mg/kg N-nitroso-N-butylurea or N-nitrosodibutylamine [9].
• N-Nitroso-N-butylurea also induced tumors of the stomach, hematopoietic system, lung, and liver [10].

Chemical compound and disease context of N-Butyl-N-nitrosourea

• Mutagenicity of methyl-, ethyl-, propyl- and butylnitrosourea towards Escherichia coli WP2 strains with varying DNA repair capabilities [11].
• Effect of leupeptin on induction of lymphoblastic leukemia in mice by N-nitrosobutylurea [12].
• Methylnitrosourea (MNU) or butylnitrosourea (BNU) was used to induce T cell lymphomas (thymomas) in BDF1 mice [13].

Biological context of N-Butyl-N-nitrosourea

• Nucleotide excision repair modulates the cytotoxic and mutagenic effects of N-n-butyl-N-nitrosourea in cultured mammalian cells as well as in mouse splenocytes in vivo [14].
• Reversion frequencies after N-butyl-N-nitrosourea exposure were 100-fold lower than after MNU and kinetics of expression of revertant colonies differed [15].

Anatomical context of N-Butyl-N-nitrosourea

• The leukaemogenic effect of N-butyl-N-nitrosourea (BNU) was studied in normal and thymectomized AKR mice which were lethally irradiated and restored with either bone-marrow (BM) or spleen cells from (AKR X AKR/T1ALD)F1 donors [16].
• H-2 histocompatibility antigens readily identified on normal lymphoid cells using reference Balb/c anti-C57Bl (H-2d anti-H-2b) alloantisera could neither be detected on the majority of transplanted leukaemias nor on 9 primary leukaemias in C57Bl mice induced by N-butyl-N-nitrosourea (BNU) [17].
• A butylnitrosourea-induced murine T-cell leukemia, L40, was transplanted in BDF1 mice; 1 X 10(3) cells killed all recipients after conditioning with 400 rad, whereas 1 X 10(5) were needed with normal recipients [18].
• T- and B-cell determination in various lymphoid tissues of mice during N-nitrosobutylurea (NBU) leukemogenesis [19].
• Induction of digestive-tract tumors in F344 rats by continuous oral administration of N-butyl-N-nitrosourea [20].

Associations of N-Butyl-N-nitrosourea with other chemical compounds

• Castrated male WF rats, given implants of pellets containing 5.0 mg diethylstilbestrol (DES), were given N-butyl-N-nitrosourea (NBU) in small amounts, which alone produced no mammary tumors in intact female rats [21].
• The ability of N-n-butyl-N-nitrosourea (BNU) and N-methyl-N-nitrosourea (MNU) to induce cytotoxicity and mutation has been compared in the Chinese hamster cell lines V79A-2 and V79/79 [22].
• The appearance of orthochromatic erythroblasts in the peripheral blood was evaluated as an index of the initial stage of leukemia induced in rats by the oral administration of N,N'-2,7-fluorenylenebisacetamide, 1-ethyl-1-nitrosourea and 1-butyl-1-nitrosourea [23].
• The leukemogenic effect of 1-propyl- and 1-butyl-1-nitrosourea (PNU and BNU) was studied in Donryu and Sprague-Dawley rats, which received the chemical in their drinking water [24].

Gene context of N-Butyl-N-nitrosourea

• ras and p53 genes are infrequently involved in N-nitroso-N-butylurea (NBU)-induced rat leukemia [25].
• In the absence of nucleotide excision repair, the additional deficiency of the DNA alkyltransferase (ATase) encoded by the constitutive ogt gene of Escherichia coli caused a marked increase in mutation induction by N-butyl-N-nitrosourea (BNU) [26].
• Correlation between infectivity of type-C RNA virus) murine leukemia virus, MLV) and development of leukemia was tested in female ICR/JCL mice treated with either 1-ethyl-1-nitrosourea (ENU) or 1-butyl-1-nitrosourea (BNU) [27].

Analytical, diagnostic and therapeutic context of N-Butyl-N-nitrosourea

• After treatment with N-butyl-N-nitrosourea, SCE frequency was similar in all three clones [28].
• Human cells that lack O6-alkylguanine DNA alkyltransferase (AT) activity can remove O6-butylguanine (O6-nBuG) produced in cellular DNA by exposure to N-n-butyl-N-nitrosourea as determined by radioimmunoassay of enzyme digests of DNA [29].
• Dams in group I received subcutaneous injections of 10 mg/rat 1-butyl-1-nitrosourea (BNU) on the days 15, 18 and 21 of pregnancy and dams in groups II-IV, 1mg/rat BNU on the same time schedule [30].
• Chemotherapy of N-nitrosobutylurea-induced W/Fu rat myeloid leukemias [31].

References